64100-62-5

Basic information

• Product Name: (S)-α-[[(1,1-Dimethylethyl)amino]methyl]-7-ethyl-2-benzofuranmethanol
• Synonyms: (S)-7-Ethyl-α-[(tert-butylamino)methyl]-2-benzofuranmethanol;(S)-α-[[(1,1-Dimethylethyl)amino]methyl]-7-ethyl-2-benzofuranmethanol;(S)-Bufuralol
• CAS NO: 64100-62-5
• Molecular Formula: C₁₆H₂₃NO₂
• Molecular Weight: 261.363
• Mol File: 64100-62-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 121-123 °C(Solv: acetone (67-64-1))
• Boiling Point: 393.2°Cat760mmHg
• Flash Point: 191.6°C
• Appearance: /
• Density: 1.066g/cm³
• CAS DataBase Reference: (S)-α-[[(1,1-Dimethylethyl)amino]methyl]-7-ethyl-2-benzofuranmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-α-[[(1,1-Dimethylethyl)amino]methyl]-7-ethyl-2-benzofuranmethanol(64100-62-5)
• EPA Substance Registry System: (S)-α-[[(1,1-Dimethylethyl)amino]methyl]-7-ethyl-2-benzofuranmethanol(64100-62-5)

Safety Data

• Hazardous Substances Data: 64100-62-5(Hazardous Substances Data)

Upstream product

• 593266-85-4 2-bromo-1-(7-ethyl-benzofuran-2-yl)ethanone 
• 75-64-9 tert-butylamine 
• 1206485-85-9 (S)-2-tosyloxy-1-(7-ethylbenzofuran-2-yl)ethanol 
• 1209385-59-0 cyano(7-ethylbenzofuran-2-yl)methyl acetate 
• 179728-76-8 7-ethylbenzofuran-2-carbaldehyde 
• 54340-62-4 bufuralol 
• 1206485-84-8 (S)-2-mesyloxy-1-(7-ethylbenzofuran-2-yl)ethanol 
• 73289-91-5 2-hydroxy-3-ethylbenzaldehyde 
• 59664-03-8 1-(7-ethylbenzofuran-2-yl)ethanone 
• 90-00-6 o-Hydroxyethylbenzene 

Downstream Products

• 64100-61-4 (+)-Bufuralol 
• 61470-08-4 4-Hydroxy-Bufuralol 
• 97733-09-0 3-tert-butyl-5(S)-<7-(1-hydroxyethyl)-2-benzofuranyl>-oxazolidinone 
• 97733-12-5 5(S)-(7-acetyl-2-benzofuranyl)-3-tert-butyl-2-oxazolidinone 
• 57704-16-2 (-)-(1S,1'RS)-1'-Hydroxybufuralol 
• 97805-59-9 (1R,1'S)-1'-Hydroxybufuralol 
• 97805-58-8 (1R,1'R)-1'-Hydroxybufuralol 
• 97733-04-5 3-tert-butyl-5(S)-(7-ethyl-2-benzofuranyl)-2-oxazolidinone 

Relevant articles and documents

A homochiral metal-organic framework as an effective asymmetric catalyst for cyanohydrin synthesis

A homochiral metal-organic framework (MOF) of an enantiopure 2,2′-dihydroxy-1,1′-biphenyl ligand was constructed. After exchanging one proton of the dihydroxyl group for Li(I) ions, the framework is shown to be a highly efficient and recyclable heterogene

Chiral separations of some β-adrenergic agonists and antagonists on AmyCoat column by HPLC

Sixteen β-adrenergic antagonists namely acebutalol, alprenolol, atenolol, bisoprolol, bopindolol, bufurolol, carazolol, celiprolol, indenolol, metaprolol, nebivolol, oxprenolol, practolol, propranolol, tertalol, and timolol, and two β-adrenergic agonists namely cimeterol and clenbuterol were resolved on AmyCoat (150 x 46 mm, 3 μm size of silica particle) by using (85:15:0.1, v/v/v), (90:10:0.1, v/v/v), and (95:05:0.1, v/v/v) combinations of η-heptane, ethanol, and diethylamine solvents, respectively. The flow rates used were 0.5, 1.0, 2.0, and 3.0 ml/min with detection at 225 nm. The values of capacity, separation, and resolution factors ranged from 0.38 to 19.70, 1.08-2.33, and 1.0 and 4.50, respectively. The maximum and minimum resolutions were achieved for celiprolol and bufurolol, respectively. The chiral recognition mechanisms were also discussed. The values of validation parameters were calculated.

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.